OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...
Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Thr...
Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology™ to improve patient experience and operat...
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced that it has receive...
Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...
DANNCE.AI raised $2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The L...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (d...
NurExone Biologic Inc. a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medici...
Stamford Health's Heart & Vascular Institute has announced it will be the first in Connecticut to offer a new, AI-powered cardiovas...
IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that the Centers for Medicare & Medicaid Services (CMS) has granted...
Novo Nordisk presented an exploratory post hoc analysis from the SELECT phase 3 cardiovascular outcomes trial that showed semaglutide 2.4 mg significantly ...
Bristol Myers Squibb (NYSE: BMY) announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio...
© 2025 Biopharma Boardroom. All Rights Reserved.
